Drug Report History

Return to report

Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.

The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.

Version v25-FR Version v16-FR
Language French French
Date Updated 2022-02-10 2021-09-14
Drug Identification Number 02229411 02229411
Brand name NAROPIN NAROPIN
Common or Proper name Naropin® (ropivacaine HCl 2mg/mL 5x200mL SU Polybag®) Naropin® (ropivacaine HCl 2mg/mL 5x200mL SU Polybag®)
Company Name ASPEN PHARMACARE CANADA INC. ASPEN PHARMACARE CANADA INC.
Ingredients ROPIVACAINE HYDROCHLORIDE ROPIVACAINE HYDROCHLORIDE
Strength(s) 2MG 2MG
Dosage form(s) SOLUTION SOLUTION
Route of administration EPIDURAL BLOCK/INFILTRATION BLOCK/INFILTRATION EPIDURAL EPIDURAL BLOCK/INFILTRATION BLOCK/INFILTRATION EPIDURAL
Packaging size 5 PP Polybag 5 PP Polybag
ATC code N01BB N01BB
ATC description ANESTHETICS, LOCAL ANESTHETICS, LOCAL
Reason for shortage Shortage of an inactive ingredient or component. Shortage of an inactive ingredient or component.
Anticipated start date 2020-12-01 2020-12-01
Actual start date 2020-12-02 2020-12-02
Estimated end date 2022-02-11 2021-12-31
Actual end date 2022-02-08
Shortage status Resolved Actual shortage
Tier 3 Status No No
Company comments VR89891CA1 VR89891CA1 Naropin® (ropivacaine HCl 2mg/mL 5x100mL SU Polybag®) is available as a replacement product PRODUCT CODE: VR89890CA1
Health Canada comments